Targeting minimal residual disease: a path to cure?

被引：123

作者：

Luskin, Marlise R. ^{[1
]}

Murakami, Mark A. ^{[1
]}

Manalis, Scott R. ^{[2
,3
,4
]}

Weinstock, David M. ^{[1
,5
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

[2] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA

[3] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA

[4] MIT, Dept Mech Engn, Cambridge, MA 02139 USA

[5] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA 02142 USA

来源：

NATURE REVIEWS CANCER | 2018年 / 18卷 / 04期

关键词：

ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CELL LUNG-CANCER; CIRCULATING TUMOR-CELLS; SINGLE CELLS; CLINICAL-SIGNIFICANCE; TYROSINE KINASE; FLOW-CYTOMETRY; ADULT PATIENTS; BREAST-CANCER;

D O I：

10.1038/nrc.2017.125

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize clonal heterogeneity and predict therapeutic sensitivity of MRD at a single-cell level. Preliminary evidence suggests that iterative detection, profiling and targeting of MRD would meaningfully improve outcomes and may even lead to cure.

引用

页码：255 / 263

页数：9

共 132 条

[1] Determining the origin of synchronous multifocal bladder cancer by exome sequencing [J].

Acar, Omer ;

Ozkurt, Ezgi ;

Demir, Gulfem ;

Sarac, Hilal ;

Alkan, Can ;

Esen, Tarik ;

Somel, Mehmet ;

Lack, Nathan A. .

BMC CANCER, 2015, 15

[2] Single cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR plus CXC chemokines [J].

Adalsteinsson, Viktor A. ;

Tahirova, Narmin ;

Tallapragada, Naren ;

Yao, Xiaosai ;

Campion, Liam ;

Angelini, Alessandro ;

Douce, Thomas B. ;

Huang, Cindy ;

Bowman, Brittany ;

Williamson, Christina A. ;

Kwon, Douglas S. ;

Wittrup, K. Dane ;

Love, J. Christopher .

INTEGRATIVE BIOLOGY, 2013, 5 (10) :1272-1281

[3] Minimum lesion detectability as a measure of PET system performance [J].

Adler, Stephen ;

Seidel, Jurgen ;

Choyke, Peter ;

Knopp, Michael V. ;

Binzel, Katherine ;

Zhang, Jun ;

Barker, Craig ;

Conant, Shielah ;

Maass-Moreno, Roberto .

EJNMMI PHYSICS, 2017, 4

[4] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].

Albain, K. ;

Anderson, S. ;

Arriagada, R. ;

Barlow, W. ;

Bergh, J. ;

Bliss, J. ;

Buyse, M. ;

Cameron, D. ;

Carrasco, E. ;

Clarke, M. ;

Correa, C. ;

Coates, A. ;

Collins, R. ;

Costantino, J. ;

Cutter, D. ;

Cuzick, J. ;

Darby, S. ;

Davidson, N. ;

Davies, C. ;

Davies, K. ;

Delmestri, A. ;

Di Leo, A. ;

Dowsett, M. ;

Elphinstone, P. ;

Evans, V. ;

Ewertz, M. ;

Gelber, R. ;

Gettins, L. ;

Geyer, C. ;

Goldhirsch, A. ;

Godwin, J. ;

Gray, R. ;

Gregory, C. ;

Hayes, D. ;

Hill, C. ;

Ingle, J. ;

Jakesz, R. ;

James, S. ;

Kaufmann, M. ;

Kerr, A. ;

MacKinnon, E. ;

McGale, P. ;

McHugh, T. ;

Norton, L. ;

Ohashi, Y. ;

Paik, S. ;

Pan, H. C. ;

Perez, E. ;

Peto, R. ;

Piccart, M. .

LANCET, 2012, 379 (9814) :432-444

[5] Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].

Andre, Thierry ;

Boni, Corrado ;

Navarro, Matilde ;

Tabernero, Josep ;

Hickish, Tamas ;

Topham, Clare ;

Bonetti, Andrea ;

Clingan, Philip ;

Bridgewater, John ;

Rivera, Fernando ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116

[6] Examining the utility of patient-derived xenograft mouse models [J].

Aparicio, Samuel ;

Hidalgo, Manuel ;

Kung, Andrew L. .

NATURE REVIEWS CANCER, 2015, 15 (05) :311-316

[7] The aggressive peripheral T-cell lymphomas: 2017 [J].

Armitage, James O. .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (07) :706-715

[8] Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial [J].

Ascierto, Paolo A. ;

McArthur, Grant A. ;

Dreno, Brigitte ;

Atkinson, Victoria ;

Liszkay, Gabrielle ;

Di Giacomo, Anna Maria ;

Mandala, Mario ;

Demidov, Lev ;

Stroyakovskiy, Daniil ;

Thomas, Luc ;

de la Cruz-Merino, Luis ;

Dutriaux, Caroline ;

Garbe, Claus ;

Yan, Yibing ;

Wongchenko, Matthew ;

Chang, Ilsung ;

Hsu, Jessie J. ;

Koralek, Daniel O. ;

Rooney, Isabelle ;

Ribas, Antoni ;

Larkin, James .

LANCET ONCOLOGY, 2016, 17 (09) :1248-1260

[9] Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia [J].

Beldjord, Kheira ;

Chevret, Sylvie ;

Asnafi, Vahid ;

Huguet, Francoise ;

Boulland, Marie-Laure ;

Leguay, Thibaut ;

Thomas, Xavier ;

Cayuela, Jean-Michel ;

Grardel, Nathalie ;

Chalandon, Yves ;

Boissel, Nicolas ;

Schaefer, Beat ;

Delabesse, Eric ;

Cave, Helene ;

Chevallier, Patrice ;

Buzyn, Agnes ;

Fest, Thierry ;

Reman, Oumedaly ;

Vernant, Jean-Paul ;

Lheritier, Veronique ;

Bene, Marie C. ;

Lafage, Marina ;

Macintyre, Elizabeth ;

Ifrah, Norbert ;

Dombret, Herve .

BLOOD, 2014, 123 (24) :3739-3749

[10] Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 [J].

Blanke, Charles D. ;

Rankin, Cathryn ;

Demetri, George D. ;

Ryan, Christopher W. ;

von Mehren, Margaret ;

Benjamin, Robert S. ;

Raymond, A. Kevin ;

Bramwell, Vivien H. C. ;

Baker, Laurence H. ;

Maki, Robert G. ;

Tanaka, Michael ;

Hecht, J. Randolph ;

Heinrich, Michael C. ;

Fletcher, Christopher D. M. ;

Crowley, John J. ;

Borden, Ernest C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :626-632

← 1 2 3 4 5 6 7 8 9 10 →